Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD reviews energy drink claims

This article was originally published in The Tan Sheet

Executive Summary

Review of comparison claims involving Living Essentials' 5-Hour Energy dietary supplement shows that "apples-to-oranges" comparisons are supported as long as advertising clearly discloses the point of comparison and "all material differences between the products," the National Advertising Division says. Brought to the Council of Better Business Bureaus unit's attention Aug. 6 by competitor Hansen Beverage Co., the case involved Living Essentials' TV, print and Internet ads that compare the amount of sugar in its one serving-size shot of product to two competitors' energy drinks, including Corona, Calif.-based Hansen's Monster Energy drink, which is a two-serving size, 16-oz. can. The ad claimed that 5-Hour Energy had zero sugar and 4 calories while Monster had 12 teaspoons of sugar and 200 calories. NAD concluded that the comparison for the purposes of showing the relative amounts of sugar in the products "was consumer-relevant as evidence indicated that both products were likely to be consumed as a single serving." However, NAD suggested the advertiser point out that its product comparison is against competitors' two-serving, 16 oz. cans. According to the inquiry report, Farmington Hills, Mich.-based Living Essentials supports NAD's decision and will follow the recommendations

You may also be interested in...



Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel